Scott D. Solomon mainly focuses on Internal medicine, Cardiology, Heart failure, Ejection fraction and Hazard ratio. The concepts of his Internal medicine study are interwoven with issues in Placebo and Surgery. His study explores the link between Cardiology and topics such as Diastole that cross with problems in Left ventricular hypertrophy.
His study in Heart failure is interdisciplinary in nature, drawing from both Candesartan, Proportional hazards model and Intensive care medicine. His Ejection fraction research is multidisciplinary, relying on both Cardiac function curve, Cause of death, Clinical endpoint and Enalapril. His studies examine the connections between Hazard ratio and genetics, as well as such issues in Diabetes mellitus, with regards to Anemia.
Scott D. Solomon focuses on Internal medicine, Cardiology, Heart failure, Ejection fraction and Myocardial infarction. His work on Hazard ratio, Heart failure with preserved ejection fraction, Valsartan and Sacubitril, Valsartan as part of his general Internal medicine study is frequently connected to In patient, thereby bridging the divide between different branches of science. His biological study spans a wide range of topics, including Proportional hazards model and Blood pressure, Diastole.
His Heart failure study combines topics from a wide range of disciplines, such as Placebo, Clinical trial and Confidence interval. His Ejection fraction research is multidisciplinary, incorporating elements of Surgery, Diabetes mellitus, Spironolactone, Atrial fibrillation and Dapagliflozin. His Cardiac resynchronization therapy research incorporates elements of Implantable cardioverter-defibrillator and Left bundle branch block.
Scott D. Solomon mostly deals with Internal medicine, Cardiology, Heart failure, Ejection fraction and Sacubitril, Valsartan. His Internal medicine research focuses on Dapagliflozin and how it relates to Diabetes type ii. His Cardiology study combines topics in areas such as Prospective cohort study, Proportional hazards model and Neprilysin.
His studies deal with areas such as Clinical trial, Diabetes mellitus, Randomized controlled trial, Confidence interval and Placebo as well as Heart failure. His work carried out in the field of Ejection fraction brings together such families of science as Omecamtiv mecarbil, Cardiac function curve, Quality of life, Blood pressure and Clinical endpoint. The Heart failure with preserved ejection fraction study combines topics in areas such as Spironolactone and Myocardial infarction.
Scott D. Solomon mainly investigates Internal medicine, Heart failure, Cardiology, Ejection fraction and Valsartan. His Internal medicine study often links to related topics such as Diabetes mellitus. The various areas that Scott D. Solomon examines in his Heart failure study include Candesartan, Placebo, Dapagliflozin and Hazard ratio.
His research in the fields of Paradigm hf overlaps with other disciplines such as In patient. His Ejection fraction study also includes fields such as
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology.
Roberto M. Lang;Michelle Bierig;Richard B. Devereux;Frank A. Flachskampf.
Journal of The American Society of Echocardiography (2005)
Guidelines for the Echocardiographic Assessment of the Right Heart in Adults: A Report from the American Society of Echocardiography Endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography
Lawrence G. Rudski;Wyman W. Lai;Jonathan Afilalo;Lanqi Hua.
Journal of The American Society of Echocardiography (2010)
Angiotensin-neprilysin inhibition versus enalapril in heart failure.
John J. V. McMurray;Milton Packer;Akshay S. Desai;Jianjian Gong.
The New England Journal of Medicine (2014)
Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both
Marc A. Pfeffer;John J.V. McMurray;Eric J. Velazquez;Jean-Lucien Rouleau.
The New England Journal of Medicine (2003)
Cardiovascular Risk Associated With Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
Scott D. Solomon;John J.V. McMurray;Marc A. Pfeffer;Janet Wittes.
The New England Journal of Medicine (2005)
Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction.
Nagesh S Anavekar;John J V McMurray;Eric J Velazquez;Scott D Solomon.
The New England Journal of Medicine (2004)
A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
Marc A Pfeffer;Emmanuel A. Burdmann;Chao Yin Chen;Mark E. Cooper.
The New England Journal of Medicine (2009)
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Marc A. Pfeffer;Brian L. Claggett;Rafael Diaz;Kenneth Dickstein.
The New England Journal of Medicine (2015)
Strategies for Multivessel Revascularization in Patients with Diabetes
Michael E. Farkouh;Michael Domanski;Lynn A. Sleeper;Flora S. Siami.
The New England Journal of Medicine (2012)
Spironolactone for Heart Failure with Preserved Ejection Fraction
Bertram Pitt;Marc A. Pfeffer;Susan F. Assmann;Robin Boineau.
The New England Journal of Medicine (2014)
Profile was last updated on December 6th, 2021.
Research.com Ranking is based on data retrieved from the Microsoft Academic Graph (MAG).
The ranking d-index is inferred from publications deemed to belong to the considered discipline.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: